Tusk Therapeutics is a UK biotechnology company with a focus on harnessing the power of the immune system to fight cancer through the development of novel immune modulating therapeutics. The company has established a diversified pipeline of antibodies against both novel and validated targets that play an important role in the body’s immune response to cancer. The company is actively pursuing three preclinical programmes, including TSK011010, a novel fully human anti-CD38 antibody. The funding sought in this application will further accelerate the development of TSK011010, enabling the company to bring it to market more quickly, benefitting cancer patients worldwide.
Get notified when we’re launching.
Want fast, powerful sales prospecting for UK companies? Signup below to find out when we're live.